ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Hematologic Malignancies

Hematologic Malignancies

Dietary, pet, and social contact restrictions did not have any effect on infectious complications in children undergoing intensive treatment of acute myeloid leukemia.

A study covering 4 decades of patients with chronic myeloid leukemia in Sweden found dramatic improvements in life expectancy since the advent of tyrosine kinase inhibitor therapy.

In this video we discuss the results of a phase III trial that studied upfront high-dose chemotherapy plus autologous stem cell transplantation (ASCT) compared to chemotherapy alone and bortezomib in newly diagnosed multiple myeloma.

The anti-CCR4 antibody mogamulizumab showed promising response rates compared to investigator’s choice in a randomized phase II trial of relapsed/refractory adult T-cell leukemia/lymphoma.

Similar survival outcomes were seen in lymphoma patients who underwent related donor haploidentical HCT and HLA-matched sibling donor transplant.

CD38 expression was associated with response to daratumumab monotherapy in patients with multiple myeloma.

Patients with follicular lymphoma that responded to rituximab but whose disease later underwent histologic transformation were found to have worse outcomes and may benefit from autologous stem cell transplantation.

Pages

Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.